Accelr8 Announces Acceptance Of Scientific Presentation, And Pilot Results With A New Rapid Test For A Major Emerging Resistance Threat
Accelr8 Technology Corporation (NYSE Amex: AXK) announced that it has received acceptance to present results for a study on 2-hour, culture-free, quantitative pathogen identification. The study was co-authored with principal investigators at the Denver Health Medical Center and the Barnes-Jewish Hospital in St. Louis. The presentation will take place at the 110th General Meeting of the American Society for Microbiology (ASM, http://www.asm.org) to be held from May 23-27 in San Diego... (Source: Health News from Medical News Today)
BioMimetic Therapeutics Presents Promising Pre-Clinical Sports Medicine Data At The 2010 ORS Meeting
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced pre-clinical data the Company will present at 1:15 CST today at the 2010 Orthopedic Research Society (ORS) meeting in New Orleans. The Company's sports medicine team will present results of two pre-clinical studies demonstrating that rhPDGF-BB, in combination with tissue specific matrix materials, promotes healing in tendon-tendon and tendon-bone injuries. In addition, in vitro data demonstrating rhPDGF-BB's ability to stimulate tenocytes (tendon cells) will also be presented... (Source: Health News from Medical News Today)
